Today, metaShape Pharma announced new preclinical data presented at the American Diabetes Association's 2026 Scientific Sessions demonstrating that MS 001, when combined with semaglutide or tirzepatide, may address several of the greatest challenges facing GLP-1 therapies today, all through a single, oral therapy
As a result, interventions capable of attenuating or reversing fibrotic remodelling hold significant therapeutic promise in cardiometabolic disease
As of this writing, CJC-1295 isn't actively progressing through new FDA clinical trials
In rare cases, medical cannabis might be appropriate and can be prescribed legally in the UK by specialist clinicians for specific conditions
Strong work
After that, side effects typically subside or go away completely